Reported Saturday, Assembly Biosciences Presents Phase 1a And Preclinical Data For ABI-5366 And ABI-1179 Herpes Candidates At STI & HIV 2025 And International Herpesvirus Workshop

-2.75%

Assembly Biosciences, Inc.

ASMB

32.58

-2.75%

– Phase 1a clinical data in healthy participants presented for both ABI-5366 and ABI-1179, novel long-acting herpes simplex virus helicase-primase inhibitor candidates –

– Preclinical data and U.S. genital herpes prevalence and treatment patterns also highlighted –

– Interim proof-of-concept Phase 1b data in participants with recurrent genital herpes expected for both candidates in fall 2025 –

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.